Literature DB >> 8323751

Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth.

B Westermark1, C H Heldin.   

Abstract

Platelet-derived growth factor (PDGF) is a potent mitogen for a variety of cell types. PDGF is made up as dimers of A and B polypeptide chains which are combined to generate the three isoforms of PDGF (AA, AB, BB). These bind with different specificities and affinities to two types of cell surface receptors (the alpha-receptor and the beta-receptor), both being members of the protein tyrosine kinase family of growth factor receptors. A number of human tumor cell lines, particularly those established from glioma and sarcoma, have been shown to produce PDGF and express the cognate receptor type. In these instances, tumor cell growth may be enhanced by an autocrine receptor activation. In other tumor cell types, where PDGF is produced in the absence of receptor expression, the growth factor may act in a paracrine fashion. This view is supported by our recent finding that human melanoma cells that have been stably transfected with a PDGF B-chain cDNA, elicit a stroma response when transplanted to nude mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323751     DOI: 10.3109/02841869309083897

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

1.  SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes.

Authors:  Randala Hamdan; Zhichao Zhou; Eugenie S Kleinerman
Journal:  Mol Cancer Res       Date:  2011-09-12       Impact factor: 5.852

2.  The effect of Emdogain and platelet-derived growth factor on the osteoinductive potential of hydroxyapatite tricalcium phosphate.

Authors:  R C Chan; V Marino; P M Bartold
Journal:  Clin Oral Investig       Date:  2011-10-28       Impact factor: 3.573

3.  A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.

Authors:  Grace K Dy; Sumithra J Mandrekar; Garth D Nelson; Jeffrey P Meyers; Araba A Adjei; Helen J Ross; Rafat H Ansari; Alan P Lyss; Philip J Stella; Steven E Schild; Julian R Molina; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

Review 4.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 5.  The road less travelled: c-kit and stem cell factor.

Authors:  W Hamel; M Westphal
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  Generation of mega brown adipose tissue in adults by controlling brown adipocyte differentiation in vivo.

Authors:  Qiqiao Du; Jieyu Wu; Carina Fischer; Takahiro Seki; Xu Jing; Juan Gao; Xingkang He; Kayoko Hosaka; Le Tong; Akihiro Yasue; Masato Miyake; Mitsuaki Sobajima; Seiichi Oyadomari; Xiaoting Sun; Yunlong Yang; Qinjun Zhou; Minghua Ge; Wei Tao; Shuzhong Yao; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

Review 7.  Ganglioside modulation of the PDGF receptor. A model for ganglioside functions.

Authors:  A J Yates; H E Saqr; J Van Brocklyn
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

Authors:  Lars Johan Nissen; Renhai Cao; Eva-Maria Hedlund; Zongwei Wang; Xing Zhao; Daniel Wetterskog; Keiko Funa; Ebba Bråkenhielm; Yihai Cao
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Clinical significance of preoperative thrombocytosis in patients who underwent radical nephrectomy for nonmetastatic renal cell carcinoma.

Authors:  Jae Young Choi; Young Hwii Ko; Phil Hyun Song
Journal:  Investig Clin Urol       Date:  2016-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.